Compass Pathways Stock Falls on Widened 4Q Loss

Dow Jones03-24 22:40

By Elias Schisgall

Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss.

Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year.

The biotechnology company on Tuesday reported a loss of $93.9 million, or $1 a share, compared with a loss of $43.3 million, or 63 cents a share, a year earlier.

Analysts surveyed by FactSet were expecting a loss of 40 cents a share.

Operating expenses fell to $46 million, from $48.4 million a year earlier. The company also recorded a $38.2 million decrease in the fair value of warrant liabilities in the most recent quarter.

The company, which is developing COMP360, a psychedelic treatment for depression, did not post any revenue during the quarter. It is scheduled to meet with the Food and Drug Administration about a New Drug Application submission strategy, and is targeting launch-readiness by the end of this year.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 24, 2026 10:40 ET (14:40 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621095649?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 22:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621095649","market":"fut","top_or_hot":-1,"title":"Compass Pathways Stock Falls on Widened 4Q Loss","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss. \n</p>\n<p>\n  Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year. \n</p>\n<p>\n  The biotechnology company on Tuesday reported a loss of $93.9 million, or $1 a share, compared with a loss of $43.3 million, or 63 cents a share, a year earlier. \n</p>\n<p>\n  Analysts surveyed by FactSet were expecting a loss of 40 cents a share. \n</p>\n<p>\n  Operating expenses fell to $46 million, from $48.4 million a year earlier. The company also recorded a $38.2 million decrease in the fair value of warrant liabilities in the most recent quarter. \n</p>\n<p>\n  The company, which is developing COMP360, a psychedelic treatment for depression, did not post any revenue during the quarter. It is scheduled to meet with the Food and Drug Administration about a New Drug Application submission strategy, and is targeting launch-readiness by the end of this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2026 10:40 ET (14:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Compass Pathways Stock Falls on Widened 4Q Loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCompass Pathways Stock Falls on Widened 4Q Loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-24 22:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss. \n</p>\n<p>\n  Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year. \n</p>\n<p>\n  The biotechnology company on Tuesday reported a loss of $93.9 million, or $1 a share, compared with a loss of $43.3 million, or 63 cents a share, a year earlier. \n</p>\n<p>\n  Analysts surveyed by FactSet were expecting a loss of 40 cents a share. \n</p>\n<p>\n  Operating expenses fell to $46 million, from $48.4 million a year earlier. The company also recorded a $38.2 million decrease in the fair value of warrant liabilities in the most recent quarter. \n</p>\n<p>\n  The company, which is developing COMP360, a psychedelic treatment for depression, did not post any revenue during the quarter. It is scheduled to meet with the Food and Drug Administration about a New Drug Application submission strategy, and is targeting launch-readiness by the end of this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2026 10:40 ET (14:40 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CMPS","symbol_name":"COMPASS Pathways plc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2621095649","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621095649","pubTimestamp":1774363200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss.Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year.The biotechnology company on Tuesday reported a loss of $93.9 million, or $1 a share, compared with a loss of $43.3 million, or 63 cents a share, a year earlier.Analysts surveyed by FactSet were expecting a loss of 40 cents a share.Operating expenses fell to $46 million, from $48.4 million a year earlier. The company also recorded a $38.2 million decrease in the fair value of warrant liabilities in the most recent quarter.The company, which is developing COMP360, a psychedelic treatment for depression, did not post any revenue during the quarter. It is scheduled to meet with the Food and Drug Administration about a New Drug Application submission strategy, and is targeting launch-readiness by the end of this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CMPS":"COMPASS Pathways plc","BK4139":"生物科技"},"translate_title":"Compass Pathways股价因第四季度亏损扩大而下跌","themeId":"8603dabb40994e59ac78c04c930c0d49","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMPS":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Compass Pathways fell after the company recorded a wider-than-expected fourth-quarter loss. \n\n\n  Shares were down 3.3% to $5.17 in Tuesday morning trading. The stock is up 66% over the past year. \n\n\n  The biotechnology company on Tuesday reported a loss of $93.9 million, or $1 a share, compared with a loss of $43.3 million, or 63 cents a share, a year earlier. \n\n\n  Analysts surveyed by FactSet were expecting a loss of 40 cents a share. \n\n\n  Operating expenses fell to $46 million, from $48.4 million a year earlier. The company also recorded a $38.2 million decrease in the fair value of warrant liabilities in the most recent quarter. \n\n\n  The company, which is developing COMP360, a psychedelic treatment for depression, did not post any revenue during the quarter. It is scheduled to meet with the Food and Drug Administration about a New Drug Application submission strategy, and is targeting launch-readiness by the end of this year. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 10:40 ET (14:40 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621095649","isCrawlerRequest":true}